PacBio

239 articles with PacBio

• PacBio to Report Fourth Quarter and Full Year 2022 Financial Results on February 16, 2023

  2/2/2023

  PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2022 financial results on Thursday, February 16, 2023, at 4:30 pm Eastern Time.

• Pacific Biosciences of California, Inc. Announces Pricing of Upsized Public Offering of Common Stock - Jan 25, 2023

  1/25/2023

  Pacific Biosciences of California, Inc. announced that it has priced its previously announced underwritten public offering of 17,500,000 shares of its common stock at a price to the public of $10.00 per share.

• Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock - Jan 24, 2023

  1/24/2023

  Pacific Biosciences of California, Inc. announced that it intends to offer and sell $150.0 million of shares of its common stock in an underwritten public offering.

• PacBio Celebrates Nature Methods Naming Long-Read Sequencing "Method of the Year"

  1/13/2023

  PacBio today celebrated long-read sequencing being named Nature Methods' "Method of the Year 2022."  

• PacBio Announces Record Orders, Including Orders for 76 Revio Systems Received in the Fourth Quarter of 2022

  1/9/2023

  PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today it received orders for 76 Revio systems in its fourth quarter ended December 31, 2022, making it the most successful product announcement in PacBio's history.

• PacBio and the University of Tokyo Announce Bioinformatics Applications Collaboration

  1/9/2023

  PacBio today announced a collaboration with the University of Tokyo , Graduate School of Medicine to study the use of long-read sequencing and novel bioinformatics methods in the hopes of better understanding the genetic causes of certain rare diseases in individuals and cohorts within the Japanese population.

• PacBio to Present at 41st Annual J.P. Morgan Healthcare Conference

  12/28/2022

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced that it will be participating in the following events at the 41st Annual J.P. Morgan Healthcare Conference:.

• PacBio and Boston Children's Hospital Collaborate to Investigate Novel Variants Inaccessible by Short-Read Sequencing

  12/6/2022

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced its HiFi sequencing technology will be used in a pilot project for the Children's Rare Disease Cohorts Initiative at Boston Children's Hospital.

• PacBio to Present at Upcoming Investor Conferences - November 11, 2022

  11/11/2022

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced that it will be participating in the following upcoming investor conferences.

• PacBio Announces Third Quarter 2022 Financial Results

  11/7/2022

  PacBio announced financial results for the quarter ended September 30, 2022.

• PacBio Announces that Euan Ashley, M.D., Ph.D., Joseph Puglisi, Ph.D., and Jay Shendure, Ph.D., Join Newly Created Scientific Advisory Board

  11/2/2022

  PacBio today announced it is bringing together a group of scientific experts to form PacBio's Scientific Advisory Board.

• PacBio to Report Third Quarter Earnings on November 7 and Host Inaugural Investor Day on November 15, 2022

  10/26/2022

  PacBio announced that it will hold its quarterly conference call to discuss its third quarter 2022 financial results on Monday, Nov. 7, 2022, at 5:00 p.m. Eastern Time.

• PacBio Announces Onso, the Highly Accurate Short-Read Sequencing Platform

  10/26/2022

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced the commencement of external beta testing of the Onso™ sequencing system.

• PacBio Announces Revio, a Revolutionary New Long Read Sequencing System Designed to Provide 15 Times More HiFi Data and Human Genomes at Scale for Under $1,000

  10/26/2022

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced the Revio™ long-read sequencing system, which will enable customers to dramatically scale their use of PacBio's celebrated HiFi sequencing technology.

• PacBio Launches Single-Cell Transcriptome Solution Ushering in a New Era of RNA Discovery

  10/20/2022

  PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the launch of its Multiplexed Arrays Sequencing (MAS-Seq) kit in partnership with the Broad Institute of MIT and Harvard and 10x Genomics, Inc.

• PacBio and Twist Bioscience Deliver Initial Portfolio of Target Enrichment Panels for HiFi Sequencing

  10/19/2022

  PacBio (NASDAQ: PACB) and Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the availability of an initial portfolio of off-the-shelf long-read gene panels.

• 

  The Top 5 Genome Sequencing Companies by Revenue

  9/30/2022

  The gene sequencing industry has really taken off in recent years. Here's a look at the top five genome sequencing companies, ranked by revenue.

• PacBio Unveils a New Method for Comprehensive, Genome-wide Tandem Repeat Analysis

  9/27/2022

  PacBio announced the availability of a new computational analysis method for profiling more than a million tandem repeats across the human genome using PacBio's native long-read HiFi sequencing data.

• PacBio to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

  9/7/2022

  PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference in New York, New York.

• PacBio Grants Equity Incentive Award to New Employee - Aug 19, 2022

  8/19/2022

  PacBio announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options covering an aggregate of 475,000 shares of PacBio common stock to the Company's recently hired Chief Commercial Officer, Jeff Eidel, under the Pacific Biosciences 2020 Inducement Equity Incentive Plan, effective on August 16, 2022.